Shamburg News · 8-K filed Nov 12, 2026, 8:29 AM EST
Vivani Medical Reports Q3 2026 Results and Announces Positive SLIM-1 Top-Line Data
VANI · Vivani Medical, Inc.
- Earnings
- Other event
- Reg FD disclosure
- Materiality: high
Vivani Medical, Inc. reported a third quarter 2026 net loss of $7.3 million, or $0.08 per share, compared with $6.5 million in the prior-year quarter, and cash, cash equivalents and restricted cash of $15.5 million as of September 30, 2026. The company also announced top-line results from the SLIM-1 Phase 1 trial, in which no treatment-related adverse events were reported in the NPM-139 group versus five of ten participants in the Wegovy group. Observed four-week weight loss was 0.79% for NPM-139 and 0.82% for Wegovy.
Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, 8.01, accession 0001753926-26-002108.
Written from the filing by Shamburg Markets. Figures are as reported by the company.